Drugs / IMA901
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00523159 | May 2007 → Aug 2009 | renal cell carcinoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01265901 | Dec 2010 → Jul 2015 | renal cell carcinoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00523159 ↗ |
| Modality | Vaccine | “the cancer vaccine IMA901” NCT00523159 ↗ |